Transcranial brain sonography for Parkinsonian syndromes.

Transcranial brain sonography for Parkinsonian syndromes. J Neurosurg Sci. 2019 Aug;63(4):441-449 Authors: Bor-Seng-Shu E, Paschoal FM, Almeida KJ, De Lima Oliveira M, Nogueira RC, Teixeira MJ, Walter U Abstract Substantia nigra (SN) hyperechogenicity has been proved to be a characteristic finding for idiopathic Parkinson's disease (PD), occurring in more than 90% of the patients. This echofeature is owed to increased amounts of iron in the SN region and reflects a functional impairment of the nigrostriatal dopaminergic system. In a prospective blinded study in which a group of patients with early mild signs and symptoms of unclear Parkinsonism were followed until a definite clinical diagnosis of PD, the hyperechogenicity of the SN was demonstrated to be highly predictive of a final diagnosis of PD. For the diagnosis of PD in individuals with early motor symptoms, both the sensitivity and positive predictive value of SN hyperechogenicity were higher than 90% and both the specificity and negative predictive value were higher than 80%. For early differential diagnosis between PD and atypical Parkinsonian syndromes, the sensitivity and positive predictive value of SN hyperechogenicity were higher than 90%, and both the specificity and negative predictive value were higher than 80%. The diagnostic specificity is increased if combining the TCS findings of SN, lenticular nucleus and third ventricle. In asymptomatic adult subjects, SN hyperechogenicity, at least...
Source: Journal of Neurosurgical Sciences - Category: Neurosurgery Tags: J Neurosurg Sci Source Type: research

Related Links:

LOS ANGELES (AP) — Scientists are closing in on a long-sought goal — a blood test to screen people for possible signs of Alzheimer’s disease and other forms of dementia. On Monday at the Alzheimer’s Association International Conference, half a dozen research groups gave new results on various experimental tests, including one that seems 88% accurate at indicating Alzheimer’s risk. Doctors are hoping for something to use during routine exams, where most dementia symptoms are evaluated, to gauge who needs more extensive testing. Current tools such as brain scans and spinal fluid tests are too ex...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Alzheimer's Disease Dementia Source Type: news
CONCLUSION: This review helps to better understand how workplaces can contribute to later life cognitive fitness, and it offers a conceptual overview for practitioners that want to create more protective working environments or improve existing ones. PMID: 31291742 [PubMed - as supplied by publisher]
Source: American Journal of Health Promotion : AJHP - Category: International Medicine & Public Health Authors: Tags: Am J Health Promot Source Type: research
This article reviews FDG-PET studies in Parkinson ’s disease (PD), atypical parkinsonism (AP), Huntington’s disease (HD), and dystonia.Recent FindingsThe metabolic pattern of PD, disease progression, non-motor symptoms such as fatigue, depression, apathy, impulse control disorders, and cognitive impairment, and the risk of progression to dementia have been identified with FDG-PET studies. In prodromal PD, the REM sleep behavior disorder-related covariance pattern has been described. In AP, FDG-PET studies have demonstrated to be superior to D2/D3 SPECT in differentiating PD from AP. The metabolic patterns of HD...
Source: Current Neurology and Neuroscience Reports - Category: Neuroscience Source Type: research
Authors: Berardelli I, Belvisi D, Pasquini M, Fabbrini A, Petrini F, Fabbrini G Abstract Introduction: reviewed studies that assessed the treatment of psychiatric disturbances in Parkinson's disease and atypical parkinsonisms. Neuropsychiatric disturbances in these conditions are frequent and have a profound impact on quality of life of patients and of their caregivers. It is therefore important to be familiar with the appropriate pharmacological and non-pharmacological interventions for treating these disorders. Areas covered: The authors searched for papers in English in Pubmed using the following keywords: Parkinso...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
There are a number of things that can increase the risk of dementia: age, of course, as well as certain genetic profiles and behaviors such as smoking and drinking. Some of the same things that contribute to heart disease, such as high cholesterol levels and the build up of plaques in the blood vessels, can also boost the chances of developing dementia. And in a large study published in JAMA Internal Medicine conducted in the UK, researchers report another possible factor: a group of drugs known as anticholinergics. These include prescription medications for treating depression, pulmonary disease, and Parkinson’s, as...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Brain Dementia Drugs Source Type: news
Conclusions and Relevance: Exposure to several types of strong anticholinergic drugs is associated with an increased risk of dementia. These findings highlight the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. The Study in Context: Study: 46.7 million Americans have Alzheimer’s Disease brain pathology today, so it’s urgent to prevent or at least delay progression to clinical disease From Anti-Alzheimer’s ‘Magic Bullets’ to True Brain Health Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging Report: 35% of worldwide dementia cases co...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness anticholinergic anticholinergic drugs antipsychotics Benadryl dementi dementia risk diphenhydramine middle-aged older-people Parkinson's meds Source Type: blogs
Drugs that doctors often use in the treatment of overactive bladder, gastrointestinal conditions, and depression may increase dementia risk by almost half.
Source: Parkinson's Disease News From Medical News Today - Category: Neurology Tags: Alzheimer's / Dementia Source Type: news
A widely used group of drugs -- anticholinergics -- used for everything from depression to allergies and gastrointestinal conditions to Parkinson's disease, may increase risk for dementia, a new study says.
Source: Health News - - Category: Consumer Health News Source Type: news
Lewy body dementia (LBD) is a major public health problem worldwide. Prevalence of Lewy body dementia (LBD) is second only to Alzheimer's disease (AD) among people with neurodegenerative dementia.1 LBD cause earlier mortality,2 earlier nursing home admissions, poorer quality-of-life, higher costs,3 more frequent falls, and more caregivers ’ burden than AD. LBD include two overlapping clinical syndromes, dementia with Lewy bodies (DLB) and Parkinson's disease (PD) dementia (PDD). They cause more frequent and more intense neuropsychiatric symptoms including visual hallucinations, delusions, agitation, and depression than AD.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research
In the geriatric age group, few studies demonstrate the efficacy of aggressive treatment. Often, a more palliative approach is wanted; such an approach can lead to better quality of life and even a longer life. The author discusses the limits of medical interventions in the elderly, the paucity of data, and the benefits of palliation in certain medical conditions, including dementia, Parkinson, depression, arthritis, congestive heart failure, and pneumonia. The role of frailty is addressed; specific goals of palliative care are delineated, such as reduction of polypharmacy, fall prevention, pain reduction, and the central ...
Source: Primary Care: Clinics in Office Practice - Category: Primary Care Authors: Source Type: research
More News: Brain | Dementia | Depression | Iron | Neurology | Neurosurgery | Parkinson's Disease | Study